Home › Funds › Remedium Capital Partners, LLC › JBIO

Remedium Capital Partners, LLC position in JBIO

JADE BIOSCIENCES INC · Health Care

Remedium Capital Partners, LLC reported holding 1,807,814 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$25.4M, representing 9.28% of its reported portfolio and ranking #4 among its reported holdings. Remedium Capital Partners, LLC has disclosed JBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)1.81M sh
Reported value held$25.40M
Portfolio Weight9.28%
First reportedQ4 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Remedium Capital Partners, LLC's JBIO position evolved

Remedium Capital Partners, LLC first disclosed a stake in JBIO in Q4 2025 at 1,577,750 shares (US$24.3M). The position peaked in Q2 2026 at 1,577,750 shares, worth US$35.1M. Across 4 filings, Remedium Capital Partners, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,807,814 shares valued at US$25.4M — an increase of 230,064 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.58M $24.34M New
Q1 2026 1.58M $22.17M Hold
Q2 2026 1.58M $35.06M Hold
Q3 2026 1.81M $25.40M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JBIO and 13F data

JBIO (JADE BIOSCIENCES INC) is a Health Care company. 97 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JBIO

All JBIO fund holders →

FAQ

How long has Remedium Capital Partners, LLC held JBIO?

Remedium Capital Partners, LLC has disclosed JBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Remedium Capital Partners, LLC's current position in JBIO?

As of Q3 2026, Remedium Capital Partners, LLC holds 1.81M shares of JBIO (JADE BIOSCIENCES INC), valued at $25.40M, representing 9.28% of its reported portfolio and ranking #4.

Has Remedium Capital Partners, LLC been buying or selling JBIO?

In the latest 13F filing (Q3 2026), Remedium Capital Partners, LLC increased its position in JBIO. The position peaked in Q2 2026 at 1.58M shares.

Which other funds hold JBIO?

Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 97 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.